research chemical is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-10-25. Numbers and descriptions here follow the published literature rather than marketing material.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
| Property | Value | Notes |
|---|---|---|
| Common synonyms | SR9009; Stenabolic | Nickname is not a chemical name. |
| Typical analytical method | LC-MS/MS | Often with isotope-labeled internal standard. |
| Storage temperature | -20 °C | Desiccated and protected from light. |
| Solution stability | DMSO stock; avoid freeze-thaw | Store at -20 to -80 °C. |
| Regulatory status | Not approved; varies by country | May be restricted as research chemical. |
Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.
Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.
Tim Hortons has outlets on at least seven Canadian Forces Bases. TDL Group announced in March 2006, in response to a request by Chief of the Defence Staff, General Rick Hillier, its commitment to open a franchised location at the Canadian Forces operations base in Kandahar, Afghanistan. The new Kandahar location opened on July 1, 2006, in a 40-foot (12 m) trailer on the military base. The 41 staff members of the Kandahar outlet have been drawn from the Canadian Forces Personnel Support Agency who received training on such matters as how to handle a potential nuclear weapons or biological weapons attack before working at the military base. The Canadian Federal government subsidized the operation of the Kandahar outlet in the order of CAD$4–5 million per year. The Kandahar Tim Hortons closed on November 29, 2011, after serving four million cups of coffee and three million donuts over five years. The first Tim Hortons outlet at a U.S. military base was opened in 2009 at Fort Knox. The following year, a second Tim Hortons outlet was opened at Naval Station Norfolk. As of November 2011, Tim Hortons has five outlets open on four U.S. military bases. Besides the first two, they are also at Naval Air Station Oceana and two locations at the Aberdeen Proving Ground.
On January 24, 2025, less than a week into Trump's second presidency, he fired 17 independent inspectors general at federal agencies, which appeared to violate federal law that requires advance notice of dismissals to both chambers of congress with reasons given 30 days in advance. Trump also fired all Democratic but not Republican members of the Privacy and Civil Liberties Oversight Board, which would prevent the board from meeting quorum and functioning. Trump also fired members of the Equal Employment Opportunity Commission, National Labor Relations Board and 56 senior officials at USAID for allegedly attempting to thwart his priorities.
==== GSK–Pfizer joint venture ==== In December 2018, GSK announced that it, along with Pfizer, had reached an agreement to merge and combine their consumer healthcare divisions into a single entity. The combined entity would have sales of around £9.8 billion ($12.7 billion), with GSK maintaining a 68% controlling stake in the joint venture. Pfizer would own the remaining 32% shareholding. The deal builds on an earlier 2018 deal where GSK bought out Novartis' stake in the GSK-Novartis consumer healthcare joint business.
== Research == In a phase III trial, tirzepatide demonstrated clinically significant benefits among participants with obesity and heart failure with preserved ejection fraction. Over two years of follow-up, tirzepatide decreased participants' risk of major cardiovascular (CV) complications—a combined endpoint including urgent heart failure visits, hospitalizations, more frequent diuretic treatment, and CV mortality—by 38% compared to a placebo. An observational study on patients with obesity and type 2 diabetes and heart failure with preserved ejection fraction reported that tirzepatide had a lower risk of hospitalization for heart failure and all-cause death combined than sitagliptin. In a 72-week, phase IIIb open-label head-to-head trial of adults with obesity without diabetes, tirzepatide at the maximum tolerated dose produced greater mean weight loss than semaglutide and larger reductions in waist circumference, while gastrointestinal adverse events were the most common with both drugs. A 2024 systematic review found that tirzepatide demonstrates benefits in the management of metabolic dysfunction–associated steatotic liver disease.
Sources: en.wikipedia.org
== Research == Azacitidine can be used in vitro to remove methyl groups from DNA. This may weaken the effects of gene silencing mechanisms that occur prior to methylation. Certain methylations are believed to secure DNA in a silenced state, and therefore demethylation may reduce the stability of silencing signals and confer relative gene activation. Azacitidine induces tumor regression on isocitrate dehydrogenase-1 mutant glioma xenografts in mice. In research, 5-azacitidine is commonly used for promoting cardiomyocyte differentiation of adult stem cells. However, it has been suggested that this drug has a compromised efficacy as a cardiac differentiation factor because it promotes the transdifferentiation of cardiac cells to skeletal myocytes. Azacitidine also has antiviral effects in animal studies as well as its anti-cancer actions, but has not been tested for clinical use.
These drugs are non-selective serotonin receptor agonists like serotonin and are serotonergic psychedelics due to activation of the serotonin 5-HT2A receptor. α-Methylserotonin is well-studied in preclinical research, but is not known to have been tested in humans.
From the late nineteenth century until the early 1930s, light therapy was considered an effective and mainstream medical therapy in the UK for conditions such as varicose ulcer, 'sickly children' and a wide range of other conditions. Controlled trials by the medical scientist Dora Colebrook, supported by the Medical Research Council, indicated that light therapy was not effective for such a wide range of conditions.
Sources: en.wikipedia.org
Photosynthesis impairment occurs when bacteria release toxins that disrupt photosynthetic electron transport, lowering energy production and weakening algae cells. A specific example includes the production of 3,3′,5,5′‑tetrabromo‑2,2′‑biphenyldiol (4‑BP), which is a small molecule secreted by a certain strain of marine bacteria called Gammaproteobacteria. The algicidal effect of 4‑BP occurs due to interference with plastoquinone synthesis, which is a key molecule in the photosynthetic electron transport chain of phytoplankton. 4‑BP competitively binds to the active site of the enzyme responsible for plastoquinone synthesis, blocking its function and disrupting the phytoplankton's ability to photosynthesize. This disruption causes pigment loss, reduces photosynthetic efficiency, and leads to cell damage or death (lysis). This algicidal compound has been found to kill a range of different phytoplankton, including diatoms, chlorophytes, dinoflagellates and cyanobacteria.
=== Do–Dy === Martha Doan (1872–1960), American chemist who studied thallium compounds William von Eggers Doering (1917–2011), American chemist known for the total synthesis of quinine Edward Doisy (1893–1986), American biochemist, winner of the 1943 Nobel Prize in Physiology or Medicine Davorin Dolar (1921–2005), Slovenian physical chemist who studied polyelectrolyte solutions, and is regarded as a founder of modern physical chemistry teaching in Slovenia Vy Maria Dong (born 1976), American chemist who studies enantioselective catalysis and natural product synthesis David Adriaan van Dorp (1915–1995), Dutch chemist known for the first full synthesis of vitamin A Israel Dostrovsky (1918–2010), Russian (Ukraine)-born Israeli physical chemist known for separating oxygen isotopes in water Herbert Henry Dow (1866–1930), American industrial chemist, known for bromine extraction Cornelius Drebbel (1572–1633), Dutch inventor, alchemist and chemist who contributed to develop measurement and control systems, optics and chemistry Jean Baptiste Dumas (1800–1884), French chemist, best known for the determination of atomic and molecular masses weights by measuring vapor densities Helen Dyer (1895–1998), American biochemist and early cancer researcher known for studies of carcinogenesis mechanisms
It was also reported that NMDA receptor blockage augments antidepressant-like effects of lithium in the mouse forced swimming test, indicating the possible involvement of NMDA receptor/NO signaling in the action of lithium in this animal model of learned helplessness. Lithium possesses neuroprotective properties by preventing apoptosis and increasing cell longevity. Although the search for a novel lithium-specific receptor is ongoing, the high concentration of lithium compounds required to elicit a significant pharmacological effect leads mainstream researchers to believe that the existence of such a receptor is unlikely.
Sources: en.wikipedia.org
The most common approach is liquid chromatography-tandem mass spectrometry, often after extraction from blood, urine, or tissue. Ultraviolet detection and nuclear magnetic resonance spectroscopy are used mainly for reference material characterization. Isotope-labeled internal standards improve accuracy.
Solid material is usually kept at -20 °C, desiccated, and protected from light. Dimethyl sulfoxide stocks should be stored cold and subjected to minimal freeze-thaw cycles. Aqueous solutions are generally less stable and should be prepared fresh when possible.
Legality depends on the country and the intended use. It is not an approved medicine, and some places restrict or ban sales for human consumption. Buyers should verify local rules and product documentation before procurement.
SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.